ストックスクリーナーアプリを入手
2.16
3.85%
0.08
前日終値:
$2.08
開ける：
$2.07
24時間の取引高:
734.38K
Relative Volume:
1.39
時価総額：
$227.55M
収益：
$7.05M
当期純損益:
$-30.43M
株価収益率:
-5.7022
EPS:
-0.3788
ネットキャッシュフロー:
$21.84M
1週間 パフォーマンス:
+6.93%
1か月 パフォーマンス:
+3.35%
6か月 パフォーマンス:
+0.93%
1年 パフォーマンス:
-18.49%
1日の値動き範囲:
$2.0512
$2.275
1週間の範囲:
$1.92
$2.275
52週間の値動き範囲:
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
PRQR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.16 | 219.12M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-10 | アップグレード | Citigroup | Neutral → Buy |
| 2025-01-10 | 開始されました | Oppenheimer | Outperform |
| 2024-10-29 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-02-11 | ダウングレード | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | ダウングレード | Stifel | Buy → Hold |
| 2022-02-01 | 開始されました | Raymond James | Strong Buy |
| 2021-05-03 | 開始されました | Stifel | Buy |
| 2021-03-25 | 繰り返されました | Citigroup | Buy |
| 2020-11-03 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-12-19 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-11-15 | 開始されました | Citigroup | Buy |
| 2018-09-19 | 開始されました | Evercore ISI | Outperform |
| 2017-09-26 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-06-20 | 開始されました | Chardan Capital Markets | Neutral |
| 2014-10-15 | 開始されました | Deutsche Bank | Buy |
| 2014-10-13 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Proqr Therapeutics N V (PRQR) 最新ニュース
Why ProQR Therapeutics N.V. stock is considered a top pickCapital Gains Strategies & Create Passive Income With Smart Stocks - ulpravda.ru
ProQR Therapeutics N.V. (PRQR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions - Yahoo Finance
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can ProQR Therapeutics N.V. (0PQ) stock sustain double digit ROEJuly 2025 Review & Free Technical Confirmation Trade Alerts - Улправда
Can ProQR Therapeutics N.V. stock sustain market leadershipEarnings Date Calendar & Fast Profit Trading Strategies - Bollywood Helpline
How ProQR Therapeutics N.V. (0PQ) stock gains from tech spendingWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
Can ProQR Therapeutics N.V. stock hit analyst price targetsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - Улправда
Is ProQR Therapeutics N.V. stock a safe haven assetJuly 2025 Catalysts & Weekly Breakout Watchlists - Улправда
Why ProQR Therapeutics N.V. stock is a value investor pickShort Setup & Free Weekly Chart Analysis and Trade Guides - Улправда
Will ProQR Therapeutics N.V. stock maintain momentum in 20252025 Key Highlights & Community Consensus Picks - Улправда
Breakout Zone: Why ProQR Therapeutics N.V. (0PQ) stock stays undervaluedWeekly Stock Summary & Low Risk High Reward Trade Ideas - Улправда
Will ProQR Therapeutics N.V. (0PQ) stock justify high valuationTrade Analysis Summary & Long-Term Growth Portfolio Plans - Улправда
Bull Run: Is ProQR Therapeutics N.V. stock a buy in volatile marketsMarket Trend Review & Real-Time Volume Analysis - Улправда
Can ProQR Therapeutics N.V. stock sustain free cash flow growthJuly 2025 Earnings & Fast Moving Trade Plans - Улправда
Is ProQR Therapeutics N.V. (0PQ) stock nearing a technical breakoutTrade Volume Report & AI Powered Trade Plan Recommendations - DonanımHaber
Why ProQR Therapeutics N.V. (0PQ) stock stays undervalued2025 Retail Activity & Growth Focused Investment Plans - Улправда
ProQR Therapeutics N.V PRQR’s stock price falss traction on Friday - uspostnews.com
Ready to Jump After Recent Trade: ProQR Therapeutics N.V (PRQR) - setenews.com
Is ProQR Therapeutics NV 0PQ a good long term investmentDividend Stock Watch & Free Unlock Stock Analysis - earlytimes.in
Is ProQR Therapeutics N.V. (0PQ) stock a good hedge against inflationWeekly Trade Analysis & Proven Capital Preservation Tips - Newser
Is ProQR Therapeutics N.V. (0PQ) stock a buy during volatile marketsCPI Data & Weekly Top Performers Watchlists - Newser
Will ProQR Therapeutics N.V. (0PQ) stock enhance shareholder value2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
ProQR Therapeutics N.V. (PRQR) 5.47% in After-hours: Gains Ahead of Healthcare Conference - Stocks Telegraph
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - setenews.com
Can ProQR Therapeutics N.V. (0PQ) stock surprise with quarterly results2025 Market Sentiment & Growth Focused Investment Plans - Newser
ProQR Therapeutics (PRQR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can ProQR Therapeutics N.V. (0PQ) stock ride next bull market cycleJuly 2025 Short Interest & AI Powered Buy and Sell Recommendations - Newser
How ProQR Therapeutics N.V. (0PQ) stock valuation compares with sectorQuarterly Portfolio Report & Safe Capital Growth Tips - Newser
Why ProQR Therapeutics N.V. (0PQ) stock is a strong buy callMarket Risk Report & Smart Allocation Stock Tips - Newser
How ProQR Therapeutics N.V. (0PQ) stock compares with tech leaders2025 Historical Comparison & Weekly Setup with High ROI Potential - Newser
Is ProQR Therapeutics N.V. stock attractive for hedge funds2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser
ProQR Therapeutics N.V. to Participate in 8th Annual Evercore Healthcare Conference on December 4, 2025 - Quiver Quantitative
ProQR to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewswire Inc.
How ProQR Therapeutics N.V. stock benefits from global expansionQuarterly Investment Review & Comprehensive Market Scan Reports - BỘ NỘI VỤ
Taking on analysts’ expectations and winning: ProQR Therapeutics N.V (PRQR) - setenews.com
Activity Recap: Why ProQR Therapeutics N.V. stock is a value investor pickJuly 2025 Volume & Capital Protection Trade Alerts - moha.gov.vn
ProQR Therapeutics NV Stock Analysis and ForecastVWAP Trading Strategies & Market Trend Real-Time Reports - earlytimes.in
Whale Trades: Why ProQR Therapeutics N.V. stock is considered a top pick2025 Market WrapUp & Community Consensus Picks - moha.gov.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ProQR Therapeutics N.V. (0PQ.F) analyst ratings, estimates and forecasts - Yahoo Finance Singapore
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 29% Share Price Plunge Could Signal Some Risk - simplywall.st
Can ProQR Therapeutics N.V. (0PQ) stock sustain breakout momentum - newser.com
Is ProQR Therapeutics N.V. stock cheap compared to fundamentals2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - newser.com
Why analysts raise outlook for ProQR Therapeutics N.V. (0PQ) stockGap Down & High Yield Equity Trading Tips - newser.com
Is ProQR Therapeutics N.V. (0PQ) stock worth buying before Fed action2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Proqr Therapeutics N V (PRQR) 財務データ
収益
当期純利益
現金流量
EPS
28.63%
大文字化:
|
ボリューム (24 時間):